Effectiveness of novel approaches to radical cure of vivax malaria - a randomized controlled trial (EFFORT)

This is a health care facility based, randomized, controlled, open label, superiority trial with three arms.

Aims and objectives:

To assess the effectiveness of a short-course of high dose primaquine (total dose 7mg/kg given unsupervised over 7 days) (PQ7) compared to the current standard low dose primaquine regimen (total dose 3.5mg/kg given unsupervised over 14 days) (PQ14);
To assess the effectiveness of tafenoquine (single dose of 300mg) (TQ) compared to the short-course high dose primaquine regimen (PQ7);
To assess the safety of tafenoquine (TQ) compared to the high and low dose primaquine regimens (PQ7 and PQ14);
To assess the cost-effectiveness and feasibility of high dose primaquine (PQ7) and tafenoquine (TQ) compared to the current low dose primaquine regimen (PQ14).

PVIVAX